Perceptive Advisors LLC raised its position in shares of Uniqure NV (NASDAQ:QURE) by 0.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,047,950 shares of the biotechnology company’s stock after purchasing an additional 7,831 shares during the quarter. Perceptive Advisors LLC owned about 3.40% of Uniqure worth $20,529,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of QURE. OxFORD Asset Management LLP bought a new position in Uniqure during the 3rd quarter valued at $399,000. Mangrove Partners boosted its stake in Uniqure by 167.4% during the 3rd quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock valued at $1,024,000 after purchasing an additional 66,763 shares in the last quarter. First Manhattan Co. bought a new position in Uniqure during the 4th quarter valued at $1,371,000. SG Americas Securities LLC bought a new position in Uniqure during the 4th quarter valued at $119,000. Finally, Victory Capital Management Inc. bought a new position in Uniqure during the 4th quarter valued at $1,298,000. 44.05% of the stock is owned by hedge funds and other institutional investors.
QURE has been the subject of a number of research reports. HC Wainwright set a $35.00 price target on Uniqure and gave the company a “buy” rating in a research note on Tuesday, February 20th. Zacks Investment Research raised Uniqure from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Tuesday, February 6th. BidaskClub raised Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. ValuEngine raised Uniqure from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. Finally, Janney Montgomery Scott initiated coverage on Uniqure in a research note on Wednesday, January 3rd. They set a “buy” rating and a $25.00 price target for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $20.75.
In other news, CEO Matthew C. Kapusta sold 21,690 shares of the firm’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $19.87, for a total transaction of $430,980.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David Schaffer sold 2,878 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $18.53, for a total value of $53,329.34. Following the sale, the director now directly owns 15,314 shares of the company’s stock, valued at $283,768.42. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,510 shares of company stock valued at $815,776. Corporate insiders own 0.73% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Perceptive Advisors LLC Raises Holdings in Uniqure NV (QURE)” was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/03/12/perceptive-advisors-llc-raises-holdings-in-uniqure-nv-qure.html.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.